Fig. 3.

Metabolic inhibitor and TMZ sensitivity differences in human high-grade glioma cells. The anti-proliferative effects of several metabolic treatments were shown using Alamar Blue (AB) and SRB tests (RAPA – rapamycin 50 ng/ml; TMZ – temozolomide 100 μM; DOXY – doxycycline 10 μM; ETO – etomoxir 50 μM; CHL – chloroquine 50 μM; BPTES – bis-2-(5-phenylacetoamido-1,3,4- thiadiazol-2-yl)-ethyl sulfide 10 μM were applied for 72 h) in U373-U (a), U87 (b) and U251 (c) cells. The significant alterations were labelled * (p = 0.01)